S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Abbott Laboratories Outlook is Healthy: Buy the Dip
Stock market today: World shares are mixed after a tech-led retreat on Wall Street
Closing prices for crude oil, gold and other commodities
Predicting a Bear Market: 7 Signs and Why it's Tough to Do
United Airlines Soars on Earnings Beat
CSX profit drops 10% despite railroad delivering 3% more freight in first quarter
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Abbott Laboratories Outlook is Healthy: Buy the Dip
Stock market today: World shares are mixed after a tech-led retreat on Wall Street
Closing prices for crude oil, gold and other commodities
Predicting a Bear Market: 7 Signs and Why it's Tough to Do
United Airlines Soars on Earnings Beat
CSX profit drops 10% despite railroad delivering 3% more freight in first quarter
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Abbott Laboratories Outlook is Healthy: Buy the Dip
Stock market today: World shares are mixed after a tech-led retreat on Wall Street
Closing prices for crude oil, gold and other commodities
Predicting a Bear Market: 7 Signs and Why it's Tough to Do
United Airlines Soars on Earnings Beat
CSX profit drops 10% despite railroad delivering 3% more freight in first quarter
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Abbott Laboratories Outlook is Healthy: Buy the Dip
Stock market today: World shares are mixed after a tech-led retreat on Wall Street
Closing prices for crude oil, gold and other commodities
Predicting a Bear Market: 7 Signs and Why it's Tough to Do
United Airlines Soars on Earnings Beat
CSX profit drops 10% despite railroad delivering 3% more freight in first quarter

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Auris Medical Holding Ltd. stock logo
EARS
Auris Medical
$1.48
-9.2%
$2.88
$0.73
$6.60
$16.90M1.173.10 million shs86,527 shs
Immune Therapeutics, Inc. stock logo
IMUN
Immune Therapeutics
$0.09
$0.09
$0.07
$1.30
$7.78M0.4615,246 shs12 shs
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
$3.00
$1.50
$19.37
$7.07M2.899,592 shs4,300 shs
International Stem Cell Co. stock logo
ISCO
International Stem Cell
$0.07
$0.09
$0.05
$0.19
N/A0.521,355 shs1,803 shs
NRIFF
Nuvo Pharmaceuticals
$0.75
$0.30
$0.87
$8.52M1.577,337 shs3,000 shs
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Auris Medical Holding Ltd. stock logo
EARS
Auris Medical
-9.20%-26.00%-12.43%-38.33%+24.37%
Immune Therapeutics, Inc. stock logo
IMUN
Immune Therapeutics
0.00%0.00%0.00%0.00%-84.50%
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
International Stem Cell Co. stock logo
ISCO
International Stem Cell
+0.14%-6.07%-16.24%-12.21%-60.04%
NRIFF
Nuvo Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Auris Medical Holding Ltd. stock logo
EARS
Auris Medical
N/AN/AN/AN/AN/AN/AN/AN/A
Immune Therapeutics, Inc. stock logo
IMUN
Immune Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
International Stem Cell Co. stock logo
ISCO
International Stem Cell
N/AN/AN/AN/AN/AN/AN/AN/A
NRIFF
Nuvo Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Auris Medical Holding Ltd. stock logo
EARS
Auris Medical
N/AN/AN/AN/A
Immune Therapeutics, Inc. stock logo
IMUN
Immune Therapeutics
N/AN/AN/AN/A
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
N/AN/AN/AN/A
International Stem Cell Co. stock logo
ISCO
International Stem Cell
N/AN/AN/AN/A
NRIFF
Nuvo Pharmaceuticals
N/AN/AN/AN/A

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Auris Medical Holding Ltd. stock logo
EARS
Auris Medical
N/AN/AN/AN/A$1.57 per shareN/A
Immune Therapeutics, Inc. stock logo
IMUN
Immune Therapeutics
N/AN/AN/AN/A($0.03) per shareN/A
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
$23.99M0.00N/AN/A$0.05 per share0.00
International Stem Cell Co. stock logo
ISCO
International Stem Cell
$7.79MN/AN/AN/A($0.57) per shareN/A
NRIFF
Nuvo Pharmaceuticals
$52.41M0.00N/A0.82$1.59 per share0.00

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Auris Medical Holding Ltd. stock logo
EARS
Auris Medical
-$8.75MN/A0.00N/AN/AN/AN/AN/A
Immune Therapeutics, Inc. stock logo
IMUN
Immune Therapeutics
-$3.54MN/A0.00N/AN/AN/A-544.75%N/A
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
-$8.28M-$4.16N/A0.00N/A-34.51%-682.54%-78.57%N/A
International Stem Cell Co. stock logo
ISCO
International Stem Cell
-$130K-$0.03N/AN/A-2.68%-2.80%-3.77%N/A
NRIFF
Nuvo Pharmaceuticals
$2.53M$0.0418.69N/AN/A-2.81%8.02%1.11%N/A

Latest NRIFF, ISCO, EARS, INNVD, and IMUN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/28/2024Q4 2023
International Stem Cell Co. stock logo
ISCO
International Stem Cell
N/A-$0.04-$0.04-$0.04N/A$1.89 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Auris Medical Holding Ltd. stock logo
EARS
Auris Medical
N/AN/AN/AN/AN/A
Immune Therapeutics, Inc. stock logo
IMUN
Immune Therapeutics
N/AN/AN/AN/AN/A
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
N/AN/AN/AN/AN/A
International Stem Cell Co. stock logo
ISCO
International Stem Cell
N/AN/AN/AN/AN/A
NRIFF
Nuvo Pharmaceuticals
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Auris Medical Holding Ltd. stock logo
EARS
Auris Medical
N/A
3.83
3.83
Immune Therapeutics, Inc. stock logo
IMUN
Immune Therapeutics
N/AN/AN/A
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
N/A
0.68
0.36
International Stem Cell Co. stock logo
ISCO
International Stem Cell
N/A
0.73
0.47
NRIFF
Nuvo Pharmaceuticals
5.27
2.67
2.11

Ownership

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Auris Medical Holding Ltd. stock logo
EARS
Auris Medical
132,20011.42 millionN/ANot Optionable
Immune Therapeutics, Inc. stock logo
IMUN
Immune Therapeutics
283.66 million41.34 millionNot Optionable
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
122.36 millionN/ANot Optionable
International Stem Cell Co. stock logo
ISCO
International Stem Cell
29N/AN/ANot Optionable
NRIFF
Nuvo Pharmaceuticals
9911.40 millionN/ANot Optionable

NRIFF, ISCO, EARS, INNVD, and IMUN Headlines

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Auris Medical logo

Auris Medical

NASDAQ:EARS
Auris Medical Holding Ltd. engages in the development of novel products that address unmet medical needs in neurology and central nervous system disorders. It operates through Switzerland and Australia geographical segments. Its product pipeline includes AM-125, AM-201, AM301, Sonsuvi, and Keyzilen. The company was founded by Thomas Meyer in April 2003 and is headquartered in Hamilton, Bermuda.
Immune Therapeutics logo

Immune Therapeutics

OTCMKTS:IMUN
Immune Therapeutics, Inc. does not have significant operations. The company was formerly known as TNI BioTech, Inc. and changed its name to Immune Therapeutics, Inc. in October 2014. Immune Therapeutics, Inc. is based in Winter Park, Florida.
Innovus Pharmaceuticals logo

Innovus Pharmaceuticals

OTCMKTS:INNVD
Innovus Pharmaceuticals, Inc., a pharmaceutical company, engages in the development, licensing, and commercialization of non-prescription medicines and consumer care products in the United States. Its products include Zestra, a proprietary blend of essential oils to enhance desire, arousal, and satisfaction in women; EjectDelay, an over-the-counter monograph compliant benzocaine gel for premature ejaculation; Sensum+, a non-medicated cream for penile sensitivity; Zestra Glide, a water-based longer lasting lubricant; Vesele, a proprietary oral supplement for promoting sexual health; and Androferti, a natural supplement to support male reproductive health and sperm quality. The company also offers Beyond Human testosterone booster, ketones, krill oil, omega 3 fish oil, Vision Formula, blood sugar, colon cleanse, green coffee extract, and growth agent; RecalMax for brain health; UriVarx, a supplement for overactive bladder and urinary incontinence; PEVarx, a supplement for peak sexual performance; ProstaGorx, a supplement for prostate support; and FlutiCare, a nasal spray. In addition, its products include Apeaz for pain relief; AllerVarx for allergy relief; ArthriVarx for joint pain; Xyralid, a hemorrhoid cream; Can-C eye drop and eye care capsule; MZS, a melatonin formula to enhance sleep patterns; and Diabasens, a diabetic foot cream. The company's pipeline products comprise UriVarx for urinary tract infection; Xyralid suppositories for hemorrhoidal symptoms; GlucoGorx supplement, glucometer, lancing device, and GlucoGorx strip for blood sugar levels; Vesele and RecalMax nitric oxide strips. It markets and sells its products through commercial partners to primary care physicians, urologists, gynecologists, and therapists, as well as to other healthcare providers; and directly to consumers through online channels, retailers, and wholesalers. Innovus Pharmaceuticals, Inc. was founded in 2008 and is headquartered in San Diego, California.
International Stem Cell logo

International Stem Cell

OTCMKTS:ISCO
International Stem Cell Corporation, a clinical stage biotechnology company, focuses on the development of therapeutic and biomedical products in the United States, Asia, Europe, and internationally. It develops ISC- hpNSC, a neural stem cell program that has completed the Phase I clinical trial for the treatment of Parkinson's disease, as well as for treating stroke and traumatic brain injury. The company also offers anti-aging skin care products, including ProPlus Advanced Defense Complex, ProPlus Advanced Recovery Complex, ProPlus Eye Firming Complex, ProPlus Neck Firming Complex, ProPlus Advanced Aqueous Treatment, ProPlus Collagen Booster, ProPlus Elastin Booster, and ProPlus Brightening Toner. In addition, it provides human cell culture products comprising human skin cells and reagents for the study of skin disease, toxicology, or wound healing; human cells from the heart and blood vessels, and reagents to study cardiovascular disease and cancer; human bronchial and tracheal cell lines for the study of toxicity, cystic fibrosis, asthma, and pathogenesis; and human mammary epithelial cell lines for the study of breast cancer, three dimensional culture, and carcinogen screening. Its human cell culture products also comprise adult stem cells and reagents for regenerative medicine; human prostate cells and specialized medium to study prostate disease; human renal and bladder cells and media to study renal and bladder diseases; human corneal cells and media for the study of corneal disease; human female reproductive system cells for the study of cellular physiology; human skeletal muscle cells for the study of biology, diabetes, insulin receptor studies, muscle metabolism, muscle tissue repair, and myotube development; and other cell culture reagents and supplements for the growth, staining, and freezing of human cells. International Stem Cell Corporation was founded in 2001 and is headquartered in San Diego, California.

Nuvo Pharmaceuticals

OTCMKTS:NRIFF
Nuvo Pharmaceuticals, Inc. is a pharmaceutical company, which is engaged in developing innovative therapeutic pharmaceutical products. It operates through the following segments: Commercial Business, Production and Service Business and Licensing and Royalty Business. The Commercial Business segment includes Blexten, Cambia, the canadian business for Resultz and Suvexx, and mature assets. The Production and Service Business segment supplies Pennsaid to Horizon for the U.S. market and is engaged in ongoing partnering efforts for Pennsaid. The Licensing and Royalty Business segment engages in the selling of Vimovo. Nuvo Pharmaceuticals was founded on August 22, 1983 and is headquartered in Mississauga, Canada.